David van Klaveren1, Theodor A Balan2, Ewout W Steyerberg3, David M Kent4. 1. Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands; Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA. Electronic address: d.vanklaveren@erasmusmc.nl. 2. Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands. 3. Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands. 4. Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Abstract
OBJECTIVES: We aimed to compare the performance of different regression modeling approaches for the prediction of heterogeneous treatment effects. STUDY DESIGN AND SETTING: We simulated trial samples (n = 3,600; 80% power for a treatment odds ratio of 0.8) from a superpopulation (N = 1,000,000) with 12 binary risk predictors, both without and with six true treatment interactions. We assessed predictions of treatment benefit for four regression models: a "risk model" (with a constant effect of treatment assignment) and three "effect models" (including interactions of risk predictors with treatment assignment). Three novel performance measures were evaluated: calibration for benefit (i.e., observed vs. predicted risk difference in treated vs. untreated), discrimination for benefit, and prediction error for benefit. RESULTS: The risk modeling approach was well-calibrated for benefit, whereas effect models were consistently overfit, even with doubled sample sizes. Penalized regression reduced miscalibration of the effect models considerably. In terms of discrimination and prediction error, the risk modeling approach was superior in the absence of true treatment effect interactions, whereas penalized regression was optimal in the presence of true treatment interactions. CONCLUSION: A risk modeling approach yields models consistently well calibrated for benefit. Effect modeling may improve discrimination for benefit in the presence of true interactions but is prone to overfitting. Hence, effect models-including only plausible interactions-should be fitted using penalized regression.
OBJECTIVES: We aimed to compare the performance of different regression modeling approaches for the prediction of heterogeneous treatment effects. STUDY DESIGN AND SETTING: We simulated trial samples (n = 3,600; 80% power for a treatment odds ratio of 0.8) from a superpopulation (N = 1,000,000) with 12 binary risk predictors, both without and with six true treatment interactions. We assessed predictions of treatment benefit for four regression models: a "risk model" (with a constant effect of treatment assignment) and three "effect models" (including interactions of risk predictors with treatment assignment). Three novel performance measures were evaluated: calibration for benefit (i.e., observed vs. predicted risk difference in treated vs. untreated), discrimination for benefit, and prediction error for benefit. RESULTS: The risk modeling approach was well-calibrated for benefit, whereas effect models were consistently overfit, even with doubled sample sizes. Penalized regression reduced miscalibration of the effect models considerably. In terms of discrimination and prediction error, the risk modeling approach was superior in the absence of true treatment effect interactions, whereas penalized regression was optimal in the presence of true treatment interactions. CONCLUSION: A risk modeling approach yields models consistently well calibrated for benefit. Effect modeling may improve discrimination for benefit in the presence of true interactions but is prone to overfitting. Hence, effect models-including only plausible interactions-should be fitted using penalized regression.
Authors: Joshua D Wallach; Patrick G Sullivan; John F Trepanowski; Kristin L Sainani; Ewout W Steyerberg; John P A Ioannidis Journal: JAMA Intern Med Date: 2017-04-01 Impact factor: 21.873
Authors: David van Klaveren; Yvonne Vergouwe; Vasim Farooq; Patrick W Serruys; Ewout W Steyerberg Journal: J Clin Epidemiol Date: 2015-02-27 Impact factor: 6.437
Authors: Sanjay Basu; Jeremy B Sussman; Joseph Rigdon; Lauren Steimle; Brian T Denton; Rodney A Hayward Journal: PLoS Med Date: 2017-10-17 Impact factor: 11.069
Authors: Hannah N Ziobrowski; Ruifeng Cui; Eric L Ross; Howard Liu; Victor Puac-Polanco; Brett Turner; Lucinda B Leung; Robert M Bossarte; Corey Bryant; Wilfred R Pigeon; David W Oslin; Edward P Post; Alan M Zaslavsky; Jose R Zubizarreta; Andrew A Nierenberg; Alex Luedtke; Chris J Kennedy; Ronald C Kessler Journal: Psychol Med Date: 2022-02-11 Impact factor: 10.592
Authors: David M Kent; David van Klaveren; Jessica K Paulus; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg Journal: Ann Intern Med Date: 2019-11-12 Impact factor: 25.391
Authors: Richard D Riley; Thomas P A Debray; David Fisher; Miriam Hattle; Nadine Marlin; Jeroen Hoogland; Francois Gueyffier; Jan A Staessen; Jiguang Wang; Karel G M Moons; Johannes B Reitsma; Joie Ensor Journal: Stat Med Date: 2020-04-30 Impact factor: 2.373
Authors: Harriet L Mills; Julian P T Higgins; Richard W Morris; David Kessler; Jon Heron; Nicola Wiles; George Davey Smith; Kate Tilling Journal: Epidemiology Date: 2021-11-01 Impact factor: 4.822
Authors: Jack Wilkinson; Kellyn F Arnold; Eleanor J Murray; Maarten van Smeden; Kareem Carr; Rachel Sippy; Marc de Kamps; Andrew Beam; Stefan Konigorski; Christoph Lippert; Mark S Gilthorpe; Peter W G Tennant Journal: Lancet Digit Health Date: 2020-09-16
Authors: Alexandros Rekkas; Jessica K Paulus; Gowri Raman; John B Wong; Ewout W Steyerberg; Peter R Rijnbeek; David M Kent; David van Klaveren Journal: BMC Med Res Methodol Date: 2020-10-23 Impact factor: 4.615
Authors: Charlie A Sewalt; Benjamin Y Gravesteijn; Daan Nieboer; Ewout W Steyerberg; Dennis Den Hartog; David Van Klaveren Journal: BMC Emerg Med Date: 2021-08-06